PFC
ARQT icon

Phocas Financial Corp’s Arcutis Biotherapeutics ARQT Stock Holding History

Phocas Financial Corp’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
47,746
-2,553
-5% -$59.5K 0.17% 123
2026
Q1 		$1.19M Sell
50,299
-14,200
-22% -$362K 0.19% 124
2025
Q4 		$1.87M Sell
64,499
-41,808
-39% -$1.07M 0.24% 115
2025
Q3 		$2M Buy
106,307
+2,293
+2% +$36.2K 0.26% 112
2025
Q2 		$1.46M Buy
104,014
+15
+0% +$210 0.21% 109
2025
Q1 		$1.63M Buy
+103,999
New +$1.47M 0.25% 108

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Phocas Financial Corp's ARQT Position: Q2 2026 in Review

Phocas Financial Corp reduced its Arcutis Biotherapeutics (ARQT) stake by 5.1% in Q2 2026, selling an estimated $59.5K and leaving 47,746 shares worth $1.25M. The position accounts for 0.17% of the portfolio, ranked #123.

Phocas Financial Corp first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. The position peaked at $2M in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Phocas Financial Corp held 47,746 shares of Arcutis Biotherapeutics worth $1.25M as of Q2 2026.
  • Phocas Financial Corp sold 2,553 Arcutis Biotherapeutics shares in Q2 2026, an estimated $59.5K.
  • Arcutis Biotherapeutics made up 0.17% of Phocas Financial Corp's portfolio in Q2 2026, its #123 holding.
  • Phocas Financial Corp first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
  • Phocas Financial Corp's Arcutis Biotherapeutics position peaked at $2M in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.